Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, posted on X:
“BREAKING from NEJM.
In cancer patients with Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is:
- Noninferior to full-dose (5 mg BID) for VTE recurrence.
- Lower bleeding risk (12.1% vs. 15.6%).
- Safer extended anticoagulation, same protection.”
Jennifer A. Marks, Thoracic Oncologist at Georgetown Lombardi, shared this post on X, adding:
“Finally, the data for cancer-associated VTE is here! Despite some of us already doing this in other settings, I’m thankful to see this literature!”
“Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.”
Authors: Isabelle Mahé et al.
